

Notice regarding Dividends of Retained Earnings

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO, Gyo Sagara) announced that it resolved to distribute with dividends of retained earnings at the meeting of its Board of Directors held today with the record date of March 31, 2023 as described below.

The matter will be proposed at the 75th Ordinary General Shareholders' Meeting scheduled for June 22, 2023.

1. Contents of Dividends

	Amount decided	Latest forecast for dividends (Announced on May 11, 2022)	Actual amount in the previous fiscal year (ended March 2022)
Record date	March 31, 2023	March 31, 2023	March 31, 2022
Dividends per share	37.00 yen	33.00 yen	28.00 yen
Total dividends	18,071 million yen	_	13,673 million yen
Effective date	June 23, 2023	_	June 24,2022
Dividend resource	Retained earnings	_	Retained earnings

2. Reasons for the Dividends

The Company considers the return of profits to all our shareholders to be one of its most important management policies. We have a basic policy of striving to maintain a stable amount of dividends over the medium to long term and to distribute profits according to business performance.

In the fiscal year ended March 31, 2023, the exchange rate of Japanese yen continued to be weaker against US dollar than expected, and royalty and other income exceeded our initial forecast. We maintained steady performance as we revised our consolidated financial forecast upward on October 31, 2022.

Based on the above policy and taking into comprehensive consideration of the full-year financial results and financial situation, we decided to revise the previously announced year-end dividend forecast to 37.00 yen per share, an increase of 4.00 yen per share. As a result, the annual dividend with the interim dividends is expected to be 70.00 yen per share.

	Dividends per share		
Record date	End of second quarter	End of fiscal year	Total
Actual amount (FY ended March, 2023)	33.00 yen	37.00 yen	70.00 yen
Actual amount (FY ended March, 2022)	28.00 yen	28.00 yen	56.00 yen

Contact:

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com